Abstract
Patients with malignant tumors are usually accompanied with hypercoagulability state and high incidence risk of venous thromboembolism (VTE), especially in patients with pancreatic ductal adenocarcinoma (PDAC). However, conventional coagulation test is failed to identify this abnormity. We retrospectively reviewed clinical data of 78 PDAC patients and 79 age-matched controls with rapid thromboelastography (r-TEG) and conventional coagulation test. The main index of r-TEG include TEG-ACT (second), R (second), K (second), angleα (°) and MA (mm), and a short TEG-ACT, short R, a short K, a broad angleα and a prolonged MA can identify hypercoagulability. Compared with age-matched controls, the PADC patients were analyzed to have a shorter K value (72. + 24 ± 22.90 vs. 85.63 ± 32.81, P = 0.0014), increased angleα value (76.20 ± 3.68 vs. 74.415 ± 4.73, P = 0.009) and MA value (63.33 ± 7.19 vs. 60.89 ± 5.52, P = 0.18). Both TEG-ACT (101.72 ± 7.57 vs. 103.78 ± 7.33, P = 0.086) and R (32.95 ± 4.72 vs. 34.34 ± 4.61, P = 0.085) value showed no significant difference in two groups. The laboratory values for conventional coagulation test were within normal ranges: PT (11.65 ± 0.95 vs. 11.38 ± 0.79, P = 0.049), INR (1.01 ± 0.09 vs. 0.98 ± 0.08, P = 0.101), aPTT (28.75 ± 3.45 vs. 28.00 ± 2.98, P = 0.149) and TT (19.44 ± 1.12 vs. 19.69 ± 1.35, P = 0.212). Incidence rates of VTE were 3.8% (3 of 78 patients) and 1.3% (1 of 79 patients) respectively (Fisher’s exact test: P = 0.367). Several r-TEG indexes can indicate coagulation disorders within PDAC patients, but the incidence rates of VTE for both PDAC patients and normal controls had no significant difference. Compare to the control group, the potential hypercoagulability of PDAC patients did not correlate to thrombotic complications.
Similar content being viewed by others
References
Heit JA et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248
Khorana AA (2003) Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 1(12):2463–2465
Ansari D et al (2015) Pancreatic cancer and thromboembolic disease 150 years after Trousseau. Hepatobiliary Surg Nutr 4(5):325–335
Toukh M et al (2014) Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 133(1):88–95
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30
Kessler CM (2009) The link between cancer and venous thromboembolism: a review. Am J Clin Oncol 32(4):S3–S7
Chew HK et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464
Khorana AA, Fine RL (2004) Pancreatic cancer and thromboembolic disease. Lancet Oncol 5(11):655–663
Mandala M et al (2007) Venous thromboembolism predicts poor prognosis in irresectable pancreaticcancer patients. Ann Oncol 18(10):1660–1665
Pannucci CJ et al (2011) Validation of the caprini risk assessment model in plastic and reconstructive surgery patients. J Vasc Surg 212(1):105–112
Bahl V et al (2010) A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 251(2):344
Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based Clinical practice guidelines. Chest 141(2):e278S
Grant PJ et al (2016) Assessing the caprini score for risk assessment of venous thromboembolismin hospitalized medical patients. Am J Med 129(5):528–535
Liu X et al (2016) Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. Interact Cardiovasc Thorac Surg 23(4):ivw158
Zakai NA, Wright J, Cushman M (2004) Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2(12):2156–2161
Wilson D et al (2001) Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Inj-Int J Care Inj 32(10):765–770
Wehrum MJ et al (2010) Comparative assessment of hypercoagulability in women with and without gynecologic malignancies using the thromboelastograph coagulation analyzer. Blood Coagul Fibrinolysis 21(2):140–143
Akay OM et al (2009) Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 26(3):358–364
Kashuk JL et al (2009) Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery 146(4):764–774
Levy JH et al (2010) Multidisciplinary approach to the challenge of hemostasis. Anesth Analg 110(2):354
Boccaccio C, Comoglio PM (2009) Genetic link between cancer and thrombosis. J Clin Oncol 27(29):4827–4833
Khorana AA et al (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13(10):2870–2875
Poruk KE et al (2010) Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomark Prev 19(10):2605–2610
Shao B et al (2011) Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood 118(15):4015–4023
Wahrenbrock M et al (2003) Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112(6):853–862
McCrath DJ et al (2005) Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 100(6):1576–1583
Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605–1617
Lassen Kristoffer (2013) Guidelines for perioperative care for pancreaticoduodenectomy: enhanced recovery after surgery (ERAS) society recommendations. World J Surg 37:240–258
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All of the authors involved in this research declare that they have no conflict of interest.
Ethical approval
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mou, Y., Li, M., Hou, S. et al. Assessment of preoperative hypercoagulability in patients with pancreatic ductal adenocarcinoma (PDAC) using rapid thromboelastography (r-TEG). J Thromb Thrombolysis 48, 648–652 (2019). https://doi.org/10.1007/s11239-019-01908-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-019-01908-8